Gerresheimer AG Revises 2025 Financial Guidance

Duesseldorf-based Gerresheimer AG has announced an adjustment to its 2025 financial guidance. The revision is attributed to continued weak demand in the cosmetics sector and declining sales of containment solutions for oral liquid medications. Despite anticipating a stronger second half of the year, the company forecasts organic revenue growth of 1-2%, down from the previously expected 3-5%. The adjusted EBITDA margin is projected at 20%, revised from 22%, with adjusted EPS expected to decline in the low double-digit percentage range.

In line with the updated guidance, Gerresheimer's Executive Board will propose reducing the dividend for 2024 to 4% of share capital, equating to EUR 0.04 per share, down from EUR 1.25. This change aims to maintain financial flexibility. A full update on the company's Q2 and H1 results for 2025 is scheduled for July 10, 2025.